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INTRODUCTION
Mediterranean spotted fever (MSF) is a tick-borne
zoonosis caused by Rickettsia conorii. Its ﬁrst
description was made by Conor and Brush in
Tunisia in 1910, where this disease is the most
common rickettsiosis.
The characteristic symptoms are fever and rash
with the presence of a black eschar ‘tache noire’ in
the majority of cases. Early empiric therapy with
tetracycline is the standard care for any case
considered consistent with a MSF infection while
conﬁrmatory laboratory results are pending.
The aim of our study is to assess the effective-
ness of a short course of antibiotic treatment in
MSF.
MATERIALS AND METHODS
All patients diagnosed with MSF at the Department of
Infectious Diseases, University Hospital of Monastir, Tunisia,
during the period January 1987 to December 2006, were
included in this case series.
Diagnosis was considered conﬁrmed if the patients had an
MSF diagnostic score of >25 according to the scoring system
described by Raoult et al. [1].
For the analysis of the data, SPSS version 13.0 was used.
Contingency data were analysed by use of the v2 test;
continuous data were analysed by use of the Student’s t-test.
Statistical signiﬁcance was set at p £0.05.
RESULTS
A total of 200 patients were diagnosed with MSF
during the study period. Most of the cases
(n = 183) occurred between June and October.
The median age was 38.4 years (range, 15–
80 years). One hundred and twenty-three
(61.5%) of the patients were male. Direct contact
with dogs was reported in 153 (76.5%) cases.
Patients were admitted to the infectious depart-
ment after a median of 6.7 days (range 1–15) of
fever. Clinically, fever was the most common
symptom (100%), followed by rash (98.5%),
headache (76.5%), arthromyalgias (64.5%), ‘tache
noire’ (63%), conjunctival hyperaemia (23%),
local lymphoadenopathy (18%), coughing
(10.5%) and meningitis (1%).
Among the laboratory studies, leucocytosis
(white blood cell count >10 000 ⁄mm3) was found
in 133 (66.5%) patients and thrombocytopenia
(platelet count <150 000 ⁄mm3) in 132 (66%). AST
and ⁄ or ALT levels were abnormal (>50 IU ⁄mL) in
148 of 177 (83.6%) cases.
Indirect immunoﬂuorescence to R. conorii was
performed in 194 (97%) cases.
Thirty-six patients had two serum samples with
four-fold titre elevation within 2 weeks; 73 had a
single serum sample with IgG of ‡ 1:128 and IgM
of ‡ 1:64; 43 had negative serology both on
admission and in convalescence; 42 patients had
negative serology on admission and did not have
another sample taken after 2 weeks. In all patients
the diagnosis has been made on the grounds of
the Raoult criteria [1].
Dilated biomicroscopic fundus examination
showed retinal involvement in 48 of 88 patients
(54.6%). This abnormality was asymptomatic
except for four patients who had mild visual loss.
Antibiotic therapy consisted of oral tetracycline
(49%), ciproﬂoxacin (20%), doxycycline (18%),
azithromycin (12%) and josamycine (1%). The
different group regimens were comparable
regarding clinical and laboratory data.
Compared with the standard therapy with
tetracycline, disappearance of fever, arthromyal-
gias and rash were statistically more rapid
(respectively, p 0.0036, 0.009 and 0.016) in the
group treated with azithromycin (Table 1).
With doxycycline, only fever and rash disap-
peared much more quickly compared with tetra-
cycline (respectively, p 0.039 and 0.0054).
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Thirty-ﬁve patients received 3 days of cipro-
ﬂoxacin. Compared with tetracycline, ciproﬂoxa-
cin was effective but the differences were not
statistically signiﬁcant.
When compared with each other, there was no
statistical difference between the use of a 3-day
regimen with ciproﬂoxacin and 1-day regimen
with doxycycline or azithromycin.
The different regimens were equally well-tol-
erated and no major side-effects were observed.
The outcome was favourable in all patients and
no relapses were observed during follow-up.
DISCUSSION
In our study, we demonstrate that 1-day azithro-
mycin or doxycycline therapy is an effective and
safe treatment for MSF in adults. In children, 3-
day azithromycin therapy is effective [2]. A
shorter duration of this antibiotic in adults had
not been tested. It was effective in our study,
probably because azithromycin has a long half-
life. A single dose of doxycycline (200 mg) has
been shown to be sufﬁcient for MSF [3]. Efﬁcacy
of 7 days of ciproﬂoxacin has been reported [4]. In
our study, 3 days of this antibiotic was also
sufﬁcient to treat MSF.
In atypical forms of MSF, the clinician may
hesitate to use a short regimen. In these cases,
fundus examination may be helpful in the early
diagnosis of this disease [5]. In fact, retinal
involvements are frequent in MSF and observed
in 54.6% of our cases.
However, for patients with severe forms short
regimens should not be considered. Furthermore,
there is a need for more well-designed rando-
mised controlled trials to support our ﬁndings.
CONCLUSION
One-day treatments with azithromycin and doxy-
cycline are effective and may offer an effective
alternative treatment to conventional regimens,
with potential for better compliance and reduced
costs.
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Table 1. Median duration of symp-
toms in days after the beginning of
therapy
Treatment group
Tetracycline
(n = 98)
Azithromycin
(n = 24)
Doxycycline
(n = 36)
Ciproﬂoxacin
(n = 35)
7 days or more
(250 mg · 4 ⁄day)
1 day
(500 mg · 2)
1 day
(200 mg · 2)
3 days
(500 mg · 3 ⁄day)
Symptoms
Fever 3.4 ± 1.1 2.6 ± 1 2.9 ± 1.1 3 ± 1.4
Arthromyalgias 4.6 ± 1.6 3.6 ± 2 3.7 ± 1.4 4.2 ± 1.9
Rash 4.1 ± 1.3 3.1 ± 1.6 3.4 ± 1.3 4 ± 1.7
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